Compare BioSyent, Inc. with Similar Stocks
Dashboard
1
High Management Efficiency with a high ROE of 18.15%
2
Company's ability to service its debt is strong with a healthy EBIT to Interest (avg) ratio of 7.50
3
With a growth in Net Profit of 32.91%, the company declared Very Positive results in Sep 25
4
With ROE of 21.64%, it has a fair valuation with a 4.45 Price to Book Value
5
Consistent Returns over the last 3 years
Stock DNA
Pharmaceuticals & Biotechnology
CAD 177 Million (Small Cap)
21.00
NA
0.00%
-0.58
21.64%
4.45
Revenue and Profits:
Net Sales:
12 Million
(Quarterly Results - Sep 2025)
Net Profit:
3 Million
Total Returns (Price + Dividend) 
TimePeriod
Price Return
Dividend Return
Total Return
3 Months
26.53%
0%
26.53%
6 Months
29.17%
0%
29.17%
1 Year
37.78%
0%
37.78%
2 Years
80.44%
0%
80.44%
3 Years
113.79%
0%
113.79%
4 Years
86.07%
0%
86.07%
5 Years
111.46%
0%
111.46%
BioSyent, Inc. for the last several years.
Risk Adjusted Returns v/s 
News
No Recent News for the Company
Announcements 
No announcement available
Corporate Actions 
No corporate action available
Quality key factors 
Factor
Value
Sales Growth (5y)
13.72%
EBIT Growth (5y)
12.58%
EBIT to Interest (avg)
7.50
Debt to EBITDA (avg)
0
Net Debt to Equity (avg)
-0.48
Sales to Capital Employed (avg)
0.96
Tax Ratio
25.74%
Dividend Payout Ratio
29.49%
Pledged Shares
0
Institutional Holding
0
ROCE (avg)
100.69%
ROE (avg)
18.15%
Valuation key factors
Factor
Value
P/E Ratio
21
Industry P/E
Price to Book Value
4.45
EV to EBIT
14.22
EV to EBITDA
13.17
EV to Capital Employed
9.23
EV to Sales
3.66
PEG Ratio
0.91
Dividend Yield
NA
ROCE (Latest)
64.92%
ROE (Latest)
21.64%
Technicals key factors
Indicator
Weekly
Monthly
MACD
Bullish
Bullish
RSI
Bearish
Bearish
Bollinger Bands
Mildly Bullish
Mildly Bullish
Moving Averages
Bullish (Daily)
KST
Bullish
Bullish
Dow Theory
Mildly Bearish
No Trend
OBV
Mildly Bearish
No Trend
Shareholding Snapshot : Mar 2025
Shareholding Compare (%holding) 
Majority shareholders
Strategic Entities
Domestic Funds
Held in 0 Schemes (0%)
Foreign Institutions
Held by 1 Foreign Institutions (0%)
Strategic Entities with highest holding
Highest Public shareholder
Quarterly Results Snapshot (Consolidated) - Sep'25 - QoQ
Sep'25
Jun'25
Change(%)
Net Sales
12.20
10.20
19.61%
Operating Profit (PBDIT) excl Other Income
3.60
2.80
28.57%
Interest
0.00
0.00
Exceptional Items
0.00
0.00
Consolidate Net Profit
2.70
2.00
35.00%
Operating Profit Margin (Excl OI)
278.90%
252.10%
2.68%
USD in Million.
Net Sales
QoQ Growth in quarter ended Sep 2025 is 19.61% vs -7.27% in Jun 2025
Consolidated Net Profit
QoQ Growth in quarter ended Sep 2025 is 35.00% vs -13.04% in Jun 2025
Annual Results Snapshot (Consolidated) - Dec'24
Dec'24
Dec'23
Change(%)
Net Sales
35.00
31.60
10.76%
Operating Profit (PBDIT) excl Other Income
9.20
8.00
15.00%
Interest
0.10
0.10
Exceptional Items
0.00
0.00
Consolidate Net Profit
7.30
6.50
12.31%
Operating Profit Margin (Excl OI)
246.50%
238.50%
0.80%
USD in Million.
Net Sales
YoY Growth in year ended Dec 2024 is 10.76% vs 13.26% in Dec 2023
Consolidated Net Profit
YoY Growth in year ended Dec 2024 is 12.31% vs 18.18% in Dec 2023
About BioSyent, Inc. 
BioSyent, Inc.
Pharmaceuticals & Biotechnology
BioSyent Inc. is a specialty pharmaceutical company. The Company, through its subsidiary, BioSyent Pharma Inc., acquires or in-licenses and develops pharmaceutical products for sale in Canada and certain international markets. It has four business units: the Community and Women's Health Unit, which commercializes pharmaceutical products focused on improving family and women's health; the Hospital Business Unit, which sells pharmaceutical products to hospitals and hospital specialists; the International Pharmaceutical Unit, and the Legacy Business. Its products include FeraMAX 150, Cathejell Jelly, FeraMAX Powder, RepaGyn, Proktis-M, Aguettant System and Cysview. FeraMAX 150 is an oral hematinic indicated for the prevention and treatment of iron deficiency anemia. Cathejell is indicated for surface anesthesia and lubrication for various procedures. RepaGyn helps relieve dryness and promotes healing of the vaginal mucosa. It also manufactures and markets Protect-It, a non-toxic product.
Company Coordinates 
Company Details
170 Attwell Dr Suite 520 , ETOBICOKE ON : M9W 5Z5
Registrar Details






